Program
GTX-B001
A development code.
Its studies are mostly in Urticaria, led by Granular Therapeutics.
Furthest: phase 1, since Sep 12, 20251 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Granular Therapeutics | 11 open or running | phase 1since Sep 12, 2025 | Sep 12, 2025 | Aug 2027phase 1 · NCT07181369 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2025First study: phase 1 study in Cold UrticariaFirst studyNCT07181369 · 72 planned · Germany
Ahead
- Aug 2027Primary completion: phase 1 study in Cold UrticariaNCT07181369
TargetBeta
ENPP3 →read by rule
“GTX-B001 is a humanized bispecific antibody than binds with one arm to a protein called c-Kit and with the second arm to a protein called CD203c, both expressed on mast cells.”study text, by rule · the study
Other programs on ENPP3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 | Johnson & Johnson | phase 1 | 1 |
| JNJ-89862175 | Johnson & Johnson | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07181369Cold Urticaria · Germany | 1 | Recruiting | Aug 2027 | 72 |
How it is read
Names in the registry
- “GTX-B001”, 1 entry
Codes read as this program: ALY301.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.